From 1990 to 1997, 113 eligible patients with classical osteosarcoma received neo-adjuvant
chemotherapy consisting of high-dose methotrexate, cisplatin and doxorubicin. Good …

BACKGROUND: Recurrence after osteosarcoma usually leads to death; thus prognostic
factors for survival are of great importance. METHODS: Between 1983 and 2002, the …

Background: We designed the study to investigate whether methotrexate, doxorubicin, and
cisplatinum (MAP) chemotherapy strategy was still the preferred option for the survival of …

To determine whether necrosis induced by pre-operative chemotherapy correlates with the
rate of systemic and local relapse, may change the pattern of relapse and/or may modify the …

We have studied 560 patients with osteosarcoma of a limb, who had been treated by
neoadjuvant chemotherapy, in order to analyse the incidence of local and systemic …

Chemotherapy for treatment of osteosarcoma was demonstrated to be effective in
eradicating primary tumor and pulmonary metastases in the mid-twentieth century. The first …

The efficacy of neoadjuvant and adjuvant chemotherapy has been clearly established in the
treatment of osteosarcoma; however, the most active regimen remains to be identified. This …

PURPOSE: To evaluate the clinicopathologic features of extraosseous osteosarcoma (EOO),
a rare soft tissue form of osteosarcoma, and to examine its response to multimodality …

The treatment of osteosarcoma requires a multidisciplinary approach involving the family
physician, orthopedic oncologist, medical oncologist, radiologist and pathologist …

Chemotherapy in osteosarcoma has had a major impact in attaining metastasis-free
survival, and the cure rates with the use of modern regimens range from 65% to 75 …